Suchergebnisse - "2494G1JF75"

PubPharm (65)

1

Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

enthalten in: Scientific reports | 2021

von Nagot, N. | Singata-Madliki, M. | Cournil, A. | +16

2

Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children : A 6 year follow-up visit from the ANRS 12174 randomized trial

enthalten in: Medicine | 2020

von Birungi, N. | Fadnes, L. | Engebretsen, I. | +3

3

Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination : a comparative analysis

enthalten in: AIDS (London, England) | 2019

von Venkatesh, K. | Farhad, M. | Fenton, T. | +7

4

Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine : a secondary analysis of the ANRS 12174 trial

enthalten in: The lancet. HIV | 2019

von Blanche, S. | Tylleskär, T. | Peries, M. | +9

CommentIn: Lancet HIV. 2019 May;6(5):e272-e273. - PMID 30814029

5

Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings : A randomised, open-label and non-inferiority study from China

enthalten in: Indian journal of medical microbiology | 2018

von Li, L. | He, H. | Lan, Y. | +7

6

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach : an observational analysis within the randomised, open-label, EARNEST trial

enthalten in: The lancet. HIV | 2017

von Paton, N. | Kityo, C. | Thompson, J. | +112

CommentIn: Lancet HIV. 2017 Aug;4(8):e323-e324. - PMID 28495563

7

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire : the MONOD ANRS 12206 non-inferiority randomised trial

enthalten in: BMC medicine | 2017

von Dahourou, D. | Amorissani-Folquet, M. | Malateste, K. | +19

8

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r : OLE-MET substudy

enthalten in: HIV clinical trials | 2017

von Saumoy, M. | Tiraboschi, J. | Ordoñez-Llanos, J. | +6

9

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen : a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

enthalten in: The lancet. HIV | 2017

von Boyd, M. | Amin, J. | Mallon, P. | +14

CommentIn: Lancet HIV. 2017 Jun;4(6):e240. - PMID 28576610

10

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine : OLE-LIP Substudy

enthalten in: HIV clinical trials | 2016

von Crespo, M. | Navarro, J. | Martinez-Rebollar, M. | +8

1
2
3
4
5
6
7
Nächster »
[7]